Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184163 | 0.84 | HPGD (1.00) | HPGDPOLBHTTRECQLHSD17B10 | |
| SCHEMBL3204586 | 0.84 | HPGD (0.93) | HPGDPOLBHTTRECQLHSD17B10 | |
| SCHEMBL3196789 | 0.83 | HPGD (0.96) | HPGDPOLBHTTRECQLHSD17B10 | |
| SCHEMBL5721928 | 0.82 | HPGD (0.81) | HPGDPOLBHTTNPC1RAB9A | |
| SCHEMBL2638071 | 0.81 | HPGD (0.86) | HPGDPOLBHTTNPC1RAB9A | |
| SCHEMBL4111861 | 0.80 | HPGD (0.77) | HPGDPOLBHTTHSD17B10NPC1 | |
| SCHEMBL27506961 | 0.80 | HPGD (0.73) | HPGDPOLBHTTRECQLHSD17B10 | |
| SCHEMBL4160220 | 0.80 | HPGD (0.77) | HPGDHTTNPC1RAB9AL3MBTL1 | |
| SCHEMBL6221064 | 0.79 | HPGD (0.75) | HPGDPOLBHTTNPC1RAB9A | |
| SCHEMBL18325841 | 0.78 | HPGD (0.69) | HPGDPOLBHTTRECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284303-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-15 | — | — | US | disclosed |
| US-20130324529-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-05 | — | — | US | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| EP-2081572-B1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-03 | — | — | EP | disclosed |
| CN-101621998-A | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV | 2010-01-06 | — | — | CN | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
| EP-2081572-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008003665-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | HPGD 1181/4885POLB 4202/4885HTT 3726/4885 |
| US-20130324529-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | HPGD 1181/4885POLB 4202/4885HTT 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.